STERIS (STE) Stock Forecast & Price Target

STERIS
Bear Case

Investors should be bearish about investing in STERIS plc for these reasons:

• Insider selling activity has been notable recently, with Director Mohsen Sohi selling 4,058 shares on August 12, 2026, and CEO Daniel A. Carestio selling a total of 4,428 shares in early June 2026, which may signal reduced internal confidence in the stock's near-term valuation.
• The stock is currently trading at a P/E ratio of 27.46, which is relatively high compared to the broader market, and some analysts have recently lowered their price targets, such as KeyCorp reducing its objective from $291.00 to $269.00 in May 2026.
• Short interest in STERIS plc has increased significantly, with shares shorted rising to 2,316,345 as of August 14, 2026, up from 1,805,984 in late May 2026, indicating growing bearish sentiment among traders who expect the stock price to decline.
• The company faces execution risks associated with its large capital expenditures, including the $600 million chemistry center investment, which may pressure cash flow and margins in the short term before the expected efficiency gains are realized.
• STERIS plc is exposed to macroeconomic risks such as tariffs and supply chain disruptions, which could impact its global supply chain and increase costs for its healthcare and life sciences products, potentially eroding its competitive advantage.